LEADER 02983nam 2200625 450 001 9910824438803321 005 20240131150933.0 010 $a1-4094-5085-6 010 $a1-315-55792-4 010 $a1-317-03108-3 010 $a1-283-12910-8 010 $a9786613129109 010 $a1-4094-3032-4 035 $a(CKB)2550000000036726 035 $a(EBL)714110 035 $a(OCoLC)735597595 035 $a(SSID)ssj0000507438 035 $a(PQKBManifestationID)12185147 035 $a(PQKBTitleCode)TC0000507438 035 $a(PQKBWorkID)10549071 035 $a(PQKB)10049924 035 $a(MiAaPQ)EBC714110 035 $a(MiAaPQ)EBC4452927 035 $a(Au-PeEL)EBL4452927 035 $a(CaPaEBR)ebr11506663 035 $a(OCoLC)1022786361 035 $a(OCoLC)1082201404 035 $a(FINmELB)ELB139259 035 $a(EXLCZ)992550000000036726 100 $a20180224h20162011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe future of pharma $eevolutionary threats and opportunities /$fBrian D. Smith 210 1$aLondon, [England] ;$aNew York, New York :$cRoutledge,$d2016. 210 4$dİ2011 215 $a1 online resource (215 p.) 300 $aDescription based upon print version of record. 311 $a1-4094-3031-6 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aWhither pharma? The world's most important industry at a fork in the road -- Universal acid. A way to understand the complex, adaptive pharmaceutical industry -- An evolving social environment -- An evolving technological environment -- The evolution of the pharmaceutical industry -- The speciation of pharma. The new business models that will transform the industry -- Sex, forced moves and good tricks. What new capabilities will be needed to survive and thrive in the future of pharma? -- Flat, focussed tribes. Organizational structures in the future of pharma -- Gales of creative destruction. The turmoil ahead of the pharmaceutical industry. 330 $aThe Future of Pharma examines the causes of the industry's potential decline and offers a convincing and rigorous analysis of the options open to it. What emerges is a landscape defined, on the one hand, by the changing marketplace of mass-market consumers, institutional healthcare systems and wealthy individuals; and on the other by the alternate sources of commercial value - innovative therapies; super-efficient processes, supply chains and operations; and closer customer relations and increasingly tailored health services. 606 $aPharmaceutical industry 615 0$aPharmaceutical industry. 676 $a338.476151 700 $aSmith$b Brian D.$0282302 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910824438803321 996 $aThe future of pharma$93939738 997 $aUNINA